Skip to main content

Table 3 Non-fasting blood sugar, HbA1c, insulin, and lipids in SHRcp fed empagliflozin-containing diet or control diet for 10 weeks

From: Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

 

Control (n = 11–12)

SGLT2 (n = 12)

Non-fasting blood sugar (mg/dl)

227 ± 17

140 ± 6*

HbA1c (%)

1.30 ± 0.03

1.12 ± 0.02*

Insulin (ng/mL)

103.6 ± 12.2

22.4 ± 2.4*

Total cholesterol (mg/dL)

206 ± 6

207 ± 9

Triglyceride (mg/dL)

591 ± 51

812 ± 39*

Free fatty acid (mmol/L)

0.46 ± 0.03

0.48 ± 0.02

  1. Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing empagliflozin. Values are mean ± SEM. Statistical analysis was performed by unpaired Student’s t test
  2. * P < 0.01 versus control
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840